BioSpace News Archive

Phase 1 Healthy Volunteers Study Expected to Begin in Mid-Year 2020

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies

Ascentage Pharma announced that the global Phase Ib/II clinical study of APG-2575, a Bcl-2 selective inhibitor, as a single agent or in combination for the treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, has dosed its first patient in the United States.

Schrödinger announced an expanded collaboration with AstraZeneca focused on refining a biologics modeling solution with the aim of speeding up the development of antibody and protein-based therapeutic candidates.

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announced the appointment of Gigi Feng as Vice President, Global Head of Corporate Communications, effective April 20th, 2020

Invitae (NYSE: NVTA), a leading medical genetics company today announced its partnership with the Muscular Dystrophy Association (MDA) to offer sponsored, no-charge genetic testing to patients through the Detect Muscular Dystrophy program in MDA’s care center network, a network of clinics at more than 150 of the nation’s top healthcare institutions.

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced that it has submitted Piclidenoson for a compassionate use program to treat coronavirus patients to the Institutional Review Board at Rabin Medical Center.

KBP Biosciences, , today announced the appointment of Nick Hart, FCMA, as Chief Financial Officer. Mr. Hart joins KBP with more than 30 years of financial and operational leadership experience within the healthcare sector, including significant expertise in financial management governance, capital raisin

Anavex Life Sciences Corp. will hold its Annual Meeting of Shareholders (Annual Meeting) on Tuesday, April 7, 2020 at 10:00 a.m. ET.

The Average Dollar Amount, Per Each Individual E-Commerce Transaction, Increased by 49.10% Sequentially - Over the Previous Week today announced that